

EIC USA Soft-landing Programme for Health and Life Sciences

Catalogue



19 - 24 May 2024 San Francisco and Silicon Valley ● #EUeic ② @EUeic ● eic.ec.europa.eu



Contents

What is the European Innovation Council?3
The EIC Fund
The EIC USA Soft-landing Programme
European Union Delegation - San Francisco Office
Meet the Founders4
Meet the Team
Meet the Partners10



What is the European Innovation Council?

With a 10.1 billion Euro budget, the European Innovation Council (EIC) is Europe's flagship innovations programme to identify, develop and scale up breakthrough technologies and game changing innovations. It provides support throughout the whole lifecycle of a company, from early-stage research to proof of concept, technology transfer and the financing and scale up of stratups and small companies.

The EIC Fund

The EIC Fund is the 3 billion Euro investment branch of the EIC. It is Europe's largest investor for deep technologies, with a mission to invest across of European countries. The EIC focuses is investment in Health and Life Sciences and Clean Technologies. It is a part of a 95.5 billion Euro Horizon Europe initiative that aims for each the U.N. sustimability agoals by 2030.

The EIC Fund supports companies in the development and commercialization of disruptive technologies. It has an engaged network of capital providers and strategic partners to lead investment rounds or to coinvest with non-dilutive and equity funding. The investment stage is typically series A but the Fund may also participate in seed and growth rounds. The EIC is committed to the empowerment and support of female founders as well as the ambition to reduce the innovation divide among EU countries.

The EIC Soft-landing Programme

The EIC Soft-landing Programme aims to support EIC-backed companies in their commercialization strategy in interational markets by opening business avenues through soft-landing activities, putting EU innovation under the spatilight in the world's most promising markets. Soft-landing activities provide a tailored intraduction to the market, connecting founders with local experts, investors, partners and innovation supporting stakeholders that are fitted to their business. The EIC Soft-landing Programme will cover the following sectors: New Technologies/Industrial Technology; Health and Medical Care; Biotechnology and Pharme; and Clean Technologies/Energy.

European Union Delegation - San Francisco Office

The European Union Delegation's San Francisco Office serves as a vital diplomatic link between the European Union and the West Coast of the United States. Located in the heart of the vibrant tech and innovation hub, the office facilitates dialogue, cooperation, and partnerships between the EU, on the one hand, and California State and local officials, industry, academic, investors and a variety of stakeholder groups in the Bay Area and beyond, on the other. With a focus on fostering economic, cultural, and research exchange, the office plays a cucial role in promoting EU volues, policies, and inditives. Through outreach programs, events, and collaborations, it aims to deepen understanding and strengthen ties between the EU and the diverse communities of San Francisco and beyond.



Meet the Founders

ABCDx

Barcelona, Spain www.abcdx.ch



Jean Charles Sanchez CEO jeancharles sanchez®ahodx ch

Vuk Vegezzi CBO vuk.vegezzi@abcdx.ch

Actome

Freiburg, Germany www.actome.de



Akara

Dublin, Ireland www.akara.ai



Cenor McGinn CEO conor.mcginn@akara.ai

Niamh Donelly Chief Robotics Officer niamh.donnelly@akara.ai

Category: Brain Health; Clinical Trials; Diagnostics and Personalized Medicine; Digital Health

ABCDx is at the forefront of revolutionizing brain injury diagnostics through their patented suite of blood-based biomarker tests, delivering rapid and non-invasively diagnosing of critical conditions including Large Vessel Occlusion (LVO), Ischemic vs. Hemorrhagic strokes, and Traumatic Brain Injury (TBI). Their flagship product, LVOCheck, is uniquely designed for use at the point of care. In ambulances, at EBs and in hospitals. LVO rapidly analyzes blood-based markers delivering results in minutes not hours resulting in the difference between recovery and long-term disability for patients.

Category: Biotechnology; Diagnostics and Personalized Medicine; Oncology

Actome dedicates its efforts to the research, development, and commercialization of its outstanding proteomics tool called PICO, which caters to R&D, biotech, and pharmaceutical sectors. Their flagship developments include highly sensitive, absolute quantitative and multiplex targeted proteomics accessing complete cellular pathways and including as small samples as a single cell. Their focus extends beyond R&D, aiming to leverage these tools for diagnostic purpose, particularly in the anoclogy, immunology (CAR-cell therapies), and stem cell fields. They concentrate initially on areas such as signed technologies, and dowarcing high-end diagnostics. To facilitate the seamless translation of scientific breakthroughs into clinical biopharmaceutical companies, expediting the integration of scientific discoveries into practical healthcare solutions.

Category: Biotechnology; Digital Health

Akara develops AI powered robots and IoT technology to help hospitals and ambulatory services certers (ASCs) increase utilization of their operating rooms. Their technology does three things: (1) reduce the time and staff needed to clean the OR between cases; (2) callect better quality room utilization data than is possible from the EHR, and (3) prevent late arrivals to OR through automated real-time alters. They are as gin-out from a top European University and have a patented, clinically validated, market ready product (TRL 7/B) with paying customers in 2 international countries (UK and Ireland). They are currently in the process of their first US sales, and have recently signed a MOU with the number 1 ranked ASC in the US. They also recently joined Techstars Healthcare LA that has a partnership with Cedars Sinai and UCI Health.



Augmedit

The Netherlands www.augmedit.com



<u>Claartje Yoma</u> Co-Founder & CEO claartje@augmedit.com

Bluedrop Medical

Galway, Ireland www.bluedropmedical.com



<u>Chris Murphy.</u> CEO chris@bluedropmedical.com

Celtic Biotech

Dublin, Ireland www.celticbiotech.com



Paul Reid Co-Founder & CEO paul.reid@celticbiotech.com



<u>John Reid</u> Co-Founder & COO john.reid@celticbiotech.com

Category: Biotechnology; Diagnostics and Personalized Medicine; Augmented Reality

Augmedit has developed a pioneering cloud-based Augmented Reality (RR) software, enhanced with Artificial Intelligence (AI), designed specifically for the surgical field. This innovative software transforms MRI or CT scass into detailed holograms, with AI algorithms automatically segmenting crucial anatomical structures for precision. These holograms are accessible via web platforms, Augmented Reality algosses, and a dedicated patient app, offering a versatile range of viewing options. Currently, their stores is constrained being the second platform of where it serves a vital role in surgical planning, medical training, and across the Netherlands, Switzerland, France, and the Czech Republic, underscoring its acceptance and utility in diverse healthcare environments. Their upcoming introoperative guidance module, aimed at enhancing the accuracy of drain placements in neurosurgery, is set to launch in the European market this surmer.

Category: Digital Health, Medical Hardware, Diabetes

Bluedrop Medical is an early commercial stage company that uses remote patient monitoring and AI to predict and prevent diabetic foot ulcers - a 100k amputation, \$17B problem in the US. Their patented, FDA compliant, device takes the form of a standard home weight scale but is embedded with a proprietary array of 700+ temperature and image sensors. It captures visual and thermal data in a 30 second scan, which is sent to the cloud for analysis by their internal. Al augmented, monitoring team. If they see something, they reach out to the patient or provider with simple steps to prevent the ulcer. The techniques they use have been shown to prevent 70% of foot ulcers in 3 clinical trials, and are recommended by international clinical auidelines. In a 2023 study, 91% of patients were fully compliant to recommended use of Bluedrop's device. The company completed FDA compliance in 2023, and currently has 2 active commercial (paid) pilots in the US, with a further pilot with one of the largest paver/provider groups in the US to start next month. The company is raising a \$20M round, of which \$10M has already been secured.

Category: Biomanufacturing; Biotechnology; Clinical Trials; Oncology; Rare Diseases

Celtic Biotech's novel biologic, CB-24, is directed at NSCLC utilizing proteins isolated from South American rattlensolve venom. A mono-or combination therapy, it has undergone evaluation by MD Anderson and the NIH/NCL. This anti-cancer agent targets nicettinic receptors on a broad range of solid tumors. Bioassay development to commence in the near future with the Broadstone Institute (USA). The results of Celtic Biotech's Phase I trials were presented at the American Association of Cancer Research.



Immunethep

Cantanhede, Portugal www.immunethep.com



<u>Bruno Santos</u> CEO bruno.santos@immunethep.com

INBRAIN Neuroelectronics

Barcelona, Spain www.nbrain-neuroelectronics.com



Carolina Aguilar Co-Founder & CEO caguilar@inbrainneuroelectronics.com

Ligence

Vilnius, Lithuania www.ligence.io



<u>Justinas Balčiūnas</u> COO į.balciunas@ligence.io



<u>Simas Tatoris</u> CTO s.tatoris@ligence.io

Category: Diagnostics and Personalized Medicine

Immunchep develops anti-bacterial immuncherapies. Their first product is Paragon Noval Vaccine (PNV). The first multi-actorial vaccine, going into clinical trials which targets 5 different bacteria, with its groundbreaking approach of targeting the bacterial factor that is inhibiting the immune system to control the infection. PNV will replace the current pneurococcal vaccines as it has much wider coverage. It is protected by robust IP.

Category: Brain Health; Digital Health

Founded in 2020 as a spin-off from Graphene Flagship (18 EU program). IMBRAIN Neuroelectronics is using graphene to drive highly trageted neuro and bioelectronic applications. Graphene brings high density precision and unparalleled resolution compared to metals like platinum and indium. They have a strategic bioelectronic collaboration with Merck in very large pharma style indications such as anti-Inflammation. Their graphene BCI cottical module juid gat MIHRA approval for first in human and they are currently reacruiting the first patient. Additionally they gat EDA broakthrough designation for the implantable platform in movement control in Parkinson's disease. They are also faces and on epileptic seizure detection and control. A QMS is in place with their ISO 12485 bath for development and manufacturing of our graphene semiconductors technology. They have 19 potent applications with 5 grantings and they usi stando 1 do dimestor term share for their Seise B round of CSDM.

Category: Diagnostics and Personalized Medicine; Digital Health

Ligence Heart is a patented AI platform with automated echacardiagraphy interpretations and reporting, saving 50% of examination time, enhancing overall accuracy, and unlocking 52M value per clinician versity. It is CE marked under MDR and sola in Europe, FDA approval is expected by the end of 2024. They are in U.S. clinical trials at unmarous university hospitals: Johan Hopkins, Yole and Nachtwestern. Integration with a large US based PACS provider was tested and aales are foreseen after FDA approval. Leven without FDA approval. Ligence capabilities, with most of these entities aiming to buy clinical like lates ance the product passes FDA. They are in collaboration with a top 5 largest global ultrasound hardware manufacturer with an aim to use Ligence's AI tool to empower their competitive edge.



Luminate Medical

Galway, Ireland www.luminatemed.com



<u>Aaron Hannon</u> CEO aaron.hannon@luminatemed.com



Cathy O'Boyle Commercial Operations Executive cathy.oboyle@luminatemed.com

Category: Oncology, Hair Loss Therapy

Luminate Medical is on a mission to change the way we experience cancer care. They design and build products which revolutionize the patient experience of cancer treatment. They're currently building our flagship product Lijk, a wearoble medical device to reduce hair loss caused by chemotherapy, and Lilic, our next-in-partialis product to reduce peripheral nerve damage caused by chemotherapy.

Netris Pharma

Lyon, France www.netrispharma.com



CFO CFO christopheguichard@netri spharma.com

PEPTOMYC

Barcelona, Spain www.peptomyc.com



<u>Joerg Klumbis</u> CFO jklumbis@peptomyc.com



Marie-Eve Beaulieu Co-Founder & Chief Scientific Officer mbeaulieu@peptomyc.com

Category: Biotechnology

Netris is an advanced clinical stage biopharmaceutical company, developing a novel solution targeting resistance to cherantherapies and immunotherapies in ancology. Their lead product is a monoclonal antibody which is currently in 5, phase 2 clinical trials. Their target is to enter the market in 3-4 years. They recently obtained IND from the FDA to launch a clinical study in the U.S. They are located at Centre Lion Bérard, the 2nd largest comprehensive cancer center in France.

Category: Oncology

Peptomyc is revolutionizing concer treatment they are the only company that uses mini-protein theropeutics to directly inhibit MYC the central engine for cancer proliferation, survival, and resistance to treatment, deregulated in at least 70% of all cancers. Doing so, Peptomyc offers a foundational treatment to any cancer patient with hommal MYC activity, improving patients' survival and quality of life. After a successful phase I trial in all-comer solid tumos (results applicated to the successful phase I trial in all-comer solid tumos (results After a successful phase I trial in all-comer solid tumos (results Could and the Medicine in Feb 2024), Peptomyc has initiated in areas sofety and efficacy in combination with the standard of care SOC, and is boosting its pipeline - based on It patent formiles so farand a commercial-ready manufacturing process that will sustain the scale up phase of the product.



SentryX

Utrecht, Netherlands www.sentryx.nl



Floris Van Tol Medical Scientist floris@sentryx.nl

Uromems

Eybens, France www.uromems.com



Hamid Lamraoui Co-Founder & CEO hamid lamroui@uromems.com



<u>Agnès Dimey</u> CFO agnes.dimey@uromems.com

Vitalera

Barcelona, Spain www.humanitcare.com



Nuria Pastor Co-Founder & CEO nuria nastor®humanitcare.com

Category: Biomanufacturing; Biotechnology; Clinical Trials

SentryX is a clinical stage biopharmaceutical company developing implantable anesthetics; a revolutionary, non-opioid, localized approach to the treatment of acute pain after major surgery. Founded by entrepreneur Bas Oosterman and spine surgeon Jorrit-Jan Verlaan, SentryX's patented product, BR-003, is designed for co-implantation with surgical screws during spine fixation surgery. This proprietary lead product combines unique smart biomaterials with bupivacaine, an approved and widely used local pain blocker. The first-in-human clinical trial for BR-003 is nearing completion, demonstrating a 52% decrease in opioid consumption and a 36% reduction in pain during the critical first three days following spine fixation surgery. The company is preparing a single pivotal (Phase III) trial and the scaling up of its manufacturing capabilities. The results of the single pivotal trial, which will involve 200 patients across 10-15 sites in Europe, are expected in 2028 and will form the basis for an accelerated application for market approval in Europe and the US (MAA/NDA).

Category: Clinical Trials; Diagnostics and Personalized Medicine; Digital Health

Uromems has developed the first connected Artificial Urinary Sphincter (AUS), an active implantable medical device designed to treat severe Stress Urinary Incontinence (SUI) in men & women. Its breakthrough device solves all limitations of existing ones. Urocktve" is a Class III implantable medical device, consisting of a cuff that is implanted around the urethra (or the bladder neck in women) and a communicating implantable control unit, which contains the electronics, a bottery, and a unique mechatronic fluidic system that inflates and deflates the cuff, thus clasing or opening the urethral conal. They work classly with health authorities (FDA through the SteP Program) for their clinical development, over 60 international KOLS and with experts for their reinbursment strategy. They are currently raising a €60m Series C, €45m committed. They are presently launching their pivolat trials.

Category: Digital Health

Vitalera offers a unique Al-based SacS platform that is device-agnostic and pathology-independent, enabling remote patient monitoring across various conditions. Patients simply need to scan with a photo the screen of any medical device (regardless of brand and age), and vitalera instantly analyzes the vital signs and sends them directly to the patient's healthcare professionals. This technology significantly amount is the instance of the standard sends and the screen of a patient's healthcare professionals. This technology significantly amount is the standard sends and the standard sends and the collection efficiency in clinical environments such as hospitals, insurance, and nursing homes, and has been implemented in more than 0 healthcare conters including the BIMC (Harroward Medical School).



3 Meet the Team



Jean-David Malo Director of the European Innovation Council and SMEs Executive Agency (EISMEA) Jean-David.MALO@ec.europa.eu



Jilian Manus Managing Partner, Structure Capital and EIC US Venture Advisor Jilian@structure.vc



Gerard de Graaf Senior Envoy for Digital to the U.S. and Head of the EU Office in San Francisco Gerard.DE-GRAAFritec.europa.eu



Joanna Smolinska Counsellor for Digital to the U.S. and Deputy Head of the EU Office in San Francisco joanna.SMOLINSKA@eeas.europa.eu



Catherine Frideres, Project Director, EIC Soft-landing Programme team catherine.frideres@pwc.lu



Manuel Mendigutia Senior adviser of the European Innovation Council and SMEs Executive Agency (EISMEA) manuel MENDIGUTIA@ec.europa.eu



Δ

Meet the Partners



Jillian Manus, Managing Partner, Structure Capital

Jillion Manus is Managing Partner of an early-stage Silicon Valley venture fund, Structure Capital. Branded "Architects of the Zero Waste Economy", they invest in undertillized assets and excess capacity. She was named one of the top 25 early-stage Female Investors by Business Insider in 2021. She serves on numerous corporate and non-profit boards that include: Stanford University School of Medicine Board of Fellows, NASDAG Entrepreneuring Center Board of Directors, NYU Tisch School of the Arts, Communities in Schools, Sofe and Sound, Schift, Prior to Structure Capital she served as Co- Director of THI for Credit Suisse Zurich, and Director of Development for Universal and Warner Bras, she was Associate Publisher of the national Founder of Brade Strategy and Global Goal Management. Inc. A frequent global public speeker, she provides business and political commentary across numerous media platforms, including CNBC, Bloomberg and CNN. She also constit the business podcast: The Pitch."



Stanford School of Medicine in Palo Alto

A leader in the biomedical revolution, Stanford Medicine has a long tradition of leadership in pioneering research, creative teaching protocols and effective clinical therapies. Its clase proximity to the resources of the university — including the Schools of Business, Law, Humanities and Sciences, and Engineering, seamless relationship with our affiliated adult and children's hospitals, and angoing associations with the entrepreneurial endeavoors of Silicon Valley, makes this institution uniquely positioned to accelerate the pace at which new knowledge is translated into tangible health benefits.



Entrepreneurial Center www.thecenter.nasdag.org

Nasdaq Entrepreneurial Center San Francisco

The Nasdaq Entrepreneurial Center is a non-profit organisation that is building a better path for entrepreneurs worldwide. Established in 2014 with support from the Nasdaq Educational Foundation, the Center serves entrepreneurs from around the world through events, education, and mentorship. The Center's Inovation Hub is where entrepreneurs take hands-on classes and workshops; drop in for mentoring or training sessions with founders and experts from a variety of industries; and enjoy the premium space with whiteboard wells with interactive webcasting for worldwide collaboration.





INSEAD - San Francisco Hub for **Business Innovation**

INSEAD has been a global leader in business education and research for six decades. They launched the world's first 10-month MBA in Fontainebleau, France, in 1959, In 2000, they opened the Asia Campus in Singapore and became the first business school with campuses on two continents. The Middle East Campus in Abu Dhabi opened in 2010 with innovation in focus. INSEAD San Francisco Hub for Business Innovation in North America, which opened in 2020, is a space to force connections and build on 60 years of excellence. INSEAD embraces alobal citizenship, and each location draws inspiration, expertise, and connections to shape the future of business. Like the Bay Area, the Hub embodies the region's tenacity, innovation, and vibrant energy. INSEAD's mission is to bring together people, cultures, and ideas to develop responsible leaders who transform business and society.



Bay Area Council

The Bay Area Council has been at the intersection of business and civic leadership, shaping the future of the Bay Area since 1945. Today, its vision is to make the Bay Area the world's best place to live and work. More than 330 of the largest employers in the region are members. The Council's Economic Institute focuses on issues relating to technology, innovation and global business, while its science affiliate BASIC (the Bay Area Science and Innovation Consortium) connects leaders on the region's technology and life science research community.



COMMONWEALTH CLUB Commonwealth Club World Affairs of California

The Commonwealth Club World Affairs of California is the nation's oldest and largest public affairs forum. Every year, they present hundreds of forums on topics ranging across politics, culture, society, artificial intelligence and the economy. The Club is headquartered in San Francisco, with regular events in San Francisco as well as in Silicon Valley, the East Bay and the North Bay. The mission of Commonwealth Club World Affairs is to be the leading national forum open to all for the impartial discussion of public issues important to the membership, community and nation,












EIC USA Soft-landing Programme





eic.ec.europa.eu